title: Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
abstract: Activating epidermal growth factor receptor (EGFR) mutations are common in many cancers including glioblastoma. However, clinical responses to EGFR inhibitors are infrequent and short-lived. We show that the Src family kinases (SFK) Fyn and Src are effectors of oncogenic EGFR signaling, enhancing invasion and tumor cell survival in vivo. Expression of a constitutively active EGFR mutant, EGFRvIII, resulted in activating phosphorylation and physical association with Src and Fyn, promoting tumor growth and motility. Gene silencing of Fyn and Src limited EGFR- and EGFRvIII-dependent tumor cell motility. The SFK inhibitor dasatinib inhibited invasion, promoted tumor regression, and induced apoptosis in vivo, significantly prolonging survival of an orthotopic glioblastoma model expressing endogenous EGFRvIII. Dasatinib enhanced the efficacy of an anti-EGFR monoclonal antibody (mAb 806) in vivo, further limiting tumor growth and extending survival. Examination of a large cohort of clinical samples showed frequent coactivation of EGFR and SFKs in glioblastoma patients. These results establish a mechanism linking EGFR signaling with Fyn and Src activation to promote tumor progression and invasion in vivo and provide rationale for combined anti-EGFR and anti-SFK targeted therapies.
authors.affiliation: Department of Pathology and Laboratory Medicine, University of California-Los Angeles David Geffen School of Medicine, USA.
authors.forename: Kan V
authors.initials: KV
authors.lastname: Lu
authors.forename: Shaojun
authors.initials: S
authors.lastname: Zhu
authors.forename: Anna
authors.initials: A
authors.lastname: Cvrljevic
authors.forename: Tiffany T
authors.initials: TT
authors.lastname: Huang
authors.forename: Shawn
authors.initials: S
authors.lastname: Sarkaria
authors.forename: David
authors.initials: D
authors.lastname: Ahkavan
authors.forename: Julie
authors.initials: J
authors.lastname: Dang
authors.forename: Eduard B
authors.initials: EB
authors.lastname: Dinca
authors.forename: Seema B
authors.initials: SB
authors.lastname: Plaisier
authors.forename: Isaac
authors.initials: I
authors.lastname: Oderberg
authors.forename: Yohan
authors.initials: Y
authors.lastname: Lee
authors.forename: Zugen
authors.initials: Z
authors.lastname: Chen
authors.forename: Jeremy S
authors.initials: JS
authors.lastname: Caldwell
authors.forename: Yongmin
authors.initials: Y
authors.lastname: Xie
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Loo
authors.forename: David
authors.initials: D
authors.lastname: Seligson
authors.forename: Arnab
authors.initials: A
authors.lastname: Chakravari
authors.forename: Francis Y
authors.initials: FY
authors.lastname: Lee
authors.forename: Roberto
authors.initials: R
authors.lastname: Weinmann
authors.forename: Timothy F
authors.initials: TF
authors.lastname: Cloughesy
authors.forename: Stanley F
authors.initials: SF
authors.lastname: Nelson
authors.forename: Gabriele
authors.initials: G
authors.lastname: Bergers
authors.forename: Thomas
authors.initials: T
authors.lastname: Graeber
authors.forename: Frank B
authors.initials: FB
authors.lastname: Furnari
authors.forename: C David
authors.initials: CD
authors.lastname: James
authors.forename: Webster K
authors.initials: WK
authors.lastname: Cavenee
authors.forename: Terrance G
authors.initials: TG
authors.lastname: Johns
authors.forename: Paul S
authors.initials: PS
authors.lastname: Mischel
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D016543:Central Nervous System Neoplasms / Q000378:metabolism* / Q000473:pathology; D000069439:Dasatinib; D004357:Drug Synergism; D004789:Enzyme Activation; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D020868:Gene Silencing; D005909:Glioblastoma / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D051379:Mice; D009154:Mutation; D009361:Neoplasm Invasiveness; D009368:Neoplasm Transplantation; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D051076:Proto-Oncogene Proteins c-fyn / Q000378:metabolism*; D011743:Pyrimidines / Q000494:pharmacology; D015398:Signal Transduction; D013844:Thiazoles / Q000494:pharmacology; D019061:src-Family Kinases / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; C410723:epidermal growth factor receptor VIII; C518939:monoclonal antibody 806; D066246:ErbB Receptors; C494957:FYN protein, human; D051076:Proto-Oncogene Proteins c-fyn; D019061:src-Family Kinases; D000069439:Dasatinib
references.citation: Clin Cancer Res. 2006 Mar 1;12(5):1398-401
references.pmid: 16533761
references.citation: Cancer Res. 2004 Sep 15;64(18):6503-10
references.pmid: 15374961
references.citation: Cancer Res. 2006 Jun 1;66(11):5542-8
references.pmid: 16740687
references.citation: Nat Biotechnol. 2009 Jan;27(1):77-83
references.pmid: 19098899
references.citation: Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19466-71
references.pmid: 17164333
references.citation: Oncogene. 2004 Feb 12;23(6):1283-90
references.pmid: 14961077
references.citation: N Engl J Med. 2006 Jun 15;354(24):2531-41
references.pmid: 16775234
references.citation: Oncogene. 1997 May 1;14(17):2005-13
references.pmid: 9160879
references.citation: Science. 2004 Jul 16;305(5682):399-401
references.pmid: 15256671
references.citation: Clin Cancer Res. 2008 Jul 1;14(13):4284-91
references.pmid: 18594011
references.citation: Cancer Res. 2005 Oct 15;65(20):9185-9
references.pmid: 16230377
references.citation: Cancer Res. 2004 Sep 1;64(17):6166-73
references.pmid: 15342401
references.citation: Cancer Cell. 2008 Mar;13(3):235-48
references.pmid: 18328427
references.citation: Cancer Res. 2002 Jun 15;62(12):3335-9
references.pmid: 12067969
references.citation: Cancer Res. 2006 Aug 15;66(16):7864-9
references.pmid: 16912159
references.citation: Cancer Cell. 2008 Mar;13(3):206-20
references.pmid: 18328425
references.citation: Science. 2008 Sep 26;321(5897):1807-12
references.pmid: 18772396
references.citation: Cancer Res. 2005 Jul 1;65(13):5535-43
references.pmid: 15994925
references.citation: Int J Cancer. 2002 Mar 20;98(3):398-408
references.pmid: 11920591
references.citation: N Engl J Med. 2008 Mar 13;358(11):1160-74
references.pmid: 18337605
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1911-25
references.pmid: 17363548
references.citation: Nat Rev Cancer. 2007 Mar;7(3):169-81
references.pmid: 17318210
references.citation: Mol Cancer Ther. 2006 Dec;5(12):3014-22
references.pmid: 17148760
references.citation: Cancer Cell. 2004 Sep;6(3):209-14
references.pmid: 15380511
references.citation: J Neurosurg. 2007 Sep;107(3):610-6
references.pmid: 17886562
references.citation: Nature. 1970 Sep 5;227(5262):1021-3
references.pmid: 4317808
references.citation: Lab Invest. 2004 Jan;84(1):8-20
references.pmid: 14631378
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: Clin Cancer Res. 2006 Dec 1;12(23):7180-6
references.pmid: 17145844
references.citation: Clin Cancer Res. 2008 Sep 1;14(17):5447-58
references.pmid: 18765536
references.citation: Cancer Res. 2003 Jun 1;63(11):2742-6
references.pmid: 12782577
references.citation: Nature. 2008 Oct 23;455(7216):1061-8
references.pmid: 18772890
references.citation: Oncogene. 2007 May 24;26(24):3503-10
references.pmid: 17173075
references.citation: Genes Chromosomes Cancer. 2004 Jan;39(1):29-36
references.pmid: 14603439
references.citation: Cancer Cell. 2003 Aug;4(2):133-46
references.pmid: 12957288
references.citation: Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6
references.pmid: 11134512
references.citation: Cancer Cell. 2006 Mar;9(3):157-73
references.pmid: 16530701
references.citation: Clin Cancer Res. 2006 Dec 15;12(24):7232-41
references.pmid: 17189394
references.citation: Nat Rev Cancer. 2004 Jun;4(6):470-80
references.pmid: 15170449
references.citation: N Engl J Med. 2005 Nov 10;353(19):2012-24
references.pmid: 16282176
references.citation: Neurosurgery. 1997 Jan;40(1):141-51
references.pmid: 8971836
references.citation: Clin Cancer Res. 2006 Sep 15;12(18):5268-72
references.pmid: 17000658
references.citation: Mol Cancer Ther. 2007 Mar;6(3):1167-74
references.pmid: 17363510
references.citation: Breast Cancer Res Treat. 2007 Nov;105(3):319-26
references.pmid: 17268817